UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

~~December~~January 2813, ~~2022~~2023

Commission File Number: 001-36686

Forward Pharma A/S

Østergade 24A, 1st Floor

1100 Copenhagen K, Denmark

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒

Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Item 1. ~~Notice~~Receipt of ~~Delisting~~Notice from Biogen

On ~~December~~January 2813, ~~2022~~2023, ~~The~~Forward ~~Nasdaq~~Pharma ~~Stock~~A/S ~~Market~~(the ~~announced~~“Company”) ~~that~~received itnotice ~~will~~from ~~delist~~ the two ~~American~~wholly ~~Depositary Shares~~owned subsidiaries of Biogen Inc. (“~~ADS~~Biogen”) ofparty ~~Forward~~to ~~Pharma~~the ~~A/S~~Settlement and License Agreement with the Company, dated January 17, 2017 (the “~~Company~~License Agreement”)., ~~The~~of ~~Company’s~~their ~~ADSs~~exercise ~~were~~of ~~suspended~~the onoption ~~December~~to ~~28,~~purchase the intellectual property outside ~~2022,~~of ~~and~~the ~~have~~United ~~not~~States ~~traded~~associated onwith ~~Nasdaq~~the ~~since~~Company ~~that~~(the ~~time~~“Designated Countries IP”) pursuant to the License Agreement. The Company’s and ~~ADSs~~Biogen ~~were~~have ~~added~~consummated the assignment of the Designated Countries IP to ~~over-~~Biogen upon the~~-counter~~ ~~trading~~execution ~~effective~~of ~~December~~assignment agreements and the 28payment of a nominal amount by Biogen to FWP IP ApS, ~~2022~~and ~~under~~Biogen has assumed ownership and responsibility for the ~~symbol~~assigned ~~“FWPAY”~~Designated Countries IP.

Nasdaq also indicated that it will file a Form 25 with the Securities and Exchange Commission (the “SEC”) to complete the delisting. The delisting will become effective ten days after the Form 25 is filed. The Company intends to file with the SEC a Form 15 requesting the suspension of the Company’s reporting obligations.SIGNATURE

~~SIGNATURE~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	FORWARD PHARMA A/S


Date: January 13, 2023	By:	/s/ Claus Bo Svendsen
		Name: Claus Bo Svendsen
		Title: Chief Executive Officer

	FORWARD PHARMA A/S
Date: December 28, 2022	By:	/s/ Claus Bo Svendsen
		Name: Claus Bo Svendsen
		Title: Chief Executive Officer

Filing Compare · Forward Pharma A/S